Notes: Lenalidomide is a derivative of the immunomodulatory compound thalidomide (Item No. 14610).{64871} It reduces TNF-α production in isolated human peripheral blood mononuclear cells (PBMCs) and whole blood stimulated by LPS from S. minnesota (Item No. 23608; IC50s = 13 and 25 nM, respectively). Lenalidomide has been used as a building block in the synthesis of PROTACs that induce the degradation of Ikaros family zinc finger protein 1 (IKZF1) and IKZF3 in MM.1S multiple myeloma cells.{64872} Orally administered lenalidomide (250 mg/kg per day) reduces vascularization and total microvascular length in a rat mesenteric window assay.{64873} Formulations containing lenalidomide have been used in the treatment of myelodysplastic syndrome and multiple myeloma.